Videos

AMP 2024

SPORTS: Drug-Eluting Stent or Primary Bare Nitinol Stent Application vs Drug-Coated Balloons in Long SFA Lesions; HEAL Study Update

09/18/2024

In this video, Dr. Thomas Zeller discusses the latest results from the SPORTS trial and the HEAL study.

In this video, Dr. Thomas Zeller...

09/18/2024

Vascular Disease Management

Jamie Chaft, MD, Memorial Sloan Kettering Cancer Center

Videos

Updated 5-Year Data From the IMpower010 Trial

09/17/2024

Jamie Chaft , MD;

Jamie Chaft, MD, discusses the 5-year follow-up data from the IMpower010 trial which showed atezolizumab continued to provide greater improvement to disease-free survival than best supportive care for patients with resectable early-stage...

Jamie Chaft, MD, discusses the...

09/17/2024

Oncology

Videos

Updates in Polycythemia Vera Treatment and Management

09/17/2024

Gabriela Hobbs, MD, provides an overview of the latest strategies and updates regarding the management and treatment of patients with polycythemia vera.

Gabriela Hobbs, MD, provides an...

09/17/2024

Oncology

AMP 2024

ZilverPASS 5-year Results; Deep Vein Arterialization: History and Rationale

09/17/2024

Watch as Dr. Michael Siah discusses 2 of his AMP 2024 presentations on ZilverPASS and DVA.

Watch as Dr. Michael Siah...

09/17/2024

Vascular Disease Management

AMP 2024

Pooled Analysis of the DETOUR System; Risk Factors in CLI Patients That May Require DVA

09/17/2024

In this video, Dr. Zola N'Dandu discusses two of his AMP 2024 presentations.

In this video, Dr. Zola N'Dandu...

09/17/2024

Vascular Disease Management

Conference Coverage

Strategic Treatment Regimens Utilizing Approved JAK Inhibitors for Patients With Myelofibrosis

09/17/2024

At the 2024 SOHO meeting, Prithviraj Bose, MD, discusses currently available JAK inhibitors for the treatment of myelofibrosis, highlighting ruxolitinib, fedratinib, pacritinib, and momelotinib.

At the 2024 SOHO meeting,...

09/17/2024

Oncology

AMP 2024

What Is the Impact of Amputation as a Treatment for CLI? Economic Costs and Patient Consequences

09/16/2024

Watch as Mary Yost, MBA, cofounder of The Yost Group, discusses her AMP 2024 presentation on the consequences of amputation as a treatment for patients with critical limb ischemia.

Watch as Mary Yost, MBA,...

09/16/2024

Vascular Disease Management

Conference Coverage

Study Suggests Retifanlimab Plus Chemotherapy as New Standard of Care for Locally Recurrent or Metastatic Anal Cancer

09/16/2024

Sheela Rao , MBBS, MD;

Sheela Rao, MBBS, MD, discusses results from the phase 3 POD1UM-303/InterAACT 2 study which showed encouraging efficacy with retifanlimab added to standard of care chemotherapy in patients with locally recurrent or metastatic squamous cell...

Sheela Rao, MBBS, MD, discusses...

09/16/2024

Oncology

Videos

First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer

09/16/2024

Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.

Heather McArthur, MD, discusses...

09/16/2024

Oncology

Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

09/15/2024

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...

Peter Schmid, MD, PhD, discusses...

09/15/2024

Oncology